Perlmutter's Eikon Follows the IPO Trail

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

Eikon, a high-profile startup led by Merck vets, seeks an IPO

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a group of experimental cancer drugs.

Eikon Therapeutics Files for IPO to Fund Development of Experimental Cancer Treatments

Eikon Therapeutics, a biotechnology startup led by form […] The post Eikon Therapeutics Files for IPO to Fund Development of Experimental Cancer Treatments first appeared on GeneOnline News. The post Eikon Therapeutics Files for IPO to Fund Development of Experimental Cancer Treatments appeared first on GeneOnline News.